Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRNA Stock Forecast 2026-2027
$61.82
Current Price
$25.06B
Market Cap
Buy 3
Hold 17
Sell 3
Wall St Analyst Ratings
Distance to MRNA Price Targets
+27.8%
To High Target of $79.00
-27.2%
To Median Target of $45.00
-64.4%
To Low Target of $22.00
MRNA Price Momentum
-9.4%
1 Week Change
-3.3%
1 Month Change
+97.8%
1 Year Change
+109.6%
Year-to-Date Change
-27.8%
From 52W High of $85.60
+177.5%
From 52W Low of $22.28
📊 TOP ANALYST CALLS
Did MRNA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Moderna is one of their latest high-conviction picks.
Latest MRNA Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, MRNA has a neutral consensus with a median price target of $45.00 (ranging from $22.00 to $79.00). The overall analyst rating is Buy (6.1/10). Currently trading at $61.82, the median forecast implies a -27.2% downside. This outlook is supported by 3 Buy, 17 Hold, and 3 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRNA Analyst Ratings
3
Buy
17
Hold
3
Sell
MRNA Price Target Range
Low
$22.00
Average
$45.00
High
$79.00
Current: $61.82
Latest MRNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRNA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 8, 2026 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $39.00 |
| Jul 7, 2026 | RBC Capital | Luca Issi | Sector Perform | Maintains | $45.00 |
| Jul 7, 2026 | B of A Securities | Dimple Gosai | Underperform | Maintains | $38.00 |
| Jun 26, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jun 8, 2026 | B of A Securities | Underperform | Maintains | $N/A | |
| May 4, 2026 | UBS | Neutral | Maintains | $N/A | |
| May 4, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| May 4, 2026 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| May 4, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Apr 2, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| Feb 23, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Feb 17, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Feb 17, 2026 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Feb 17, 2026 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| Jan 7, 2026 | UBS | Eliana Merle | Neutral | Assumes | $34.00 |
| Dec 12, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Dec 12, 2025 | Jefferies | Hold | Initiates | $N/A | |
| Nov 21, 2025 | Piper Sandler | Overweight | Reiterates | $N/A | |
| Nov 21, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Nov 21, 2025 | Leerink Partners | Underperform | Maintains | $N/A |
Moderna, Inc. (MRNA) Competitors
The following stocks are similar to Moderna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Moderna, Inc. (MRNA) Financial Data
Moderna, Inc. has a market capitalization of $25.06B with a P/E ratio of 25.0x. The company generates $2.22B in trailing twelve-month revenue with a -143.6% profit margin.
Revenue growth is +260.2% quarter-over-quarter, while maintaining an operating margin of -131.1% and return on equity of -36.6%.
Valuation Metrics
Market Cap
$25.06B
Enterprise Value
$23.19B
P/E Ratio
25.0x
PEG Ratio
0.7x
Price/Sales
11.3x
Growth & Margins
Revenue Growth (YoY)
+260.2%
Gross Margin
-145.5%
Operating Margin
-131.1%
Net Margin
-143.6%
EPS Growth
+263.6%
Financial Health
Cash/Price Ratio
+21.2%
Current Ratio
2.4x
Debt/Equity
17.5x
ROE
-36.6%
ROA
-13.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Moderna, Inc. (MRNA) Business Model
About Moderna, Inc.
What They Do
Develops transformative mRNA-based medicines and vaccines.
Business Model
Moderna generates revenue through the development and commercialization of mRNA-based therapeutics and vaccines. The company partners with governments and health organizations for vaccine distribution and also explores collaborations with pharmaceutical companies to expand its therapeutic applications, particularly in oncology and rare diseases.
Additional Information
Founded in 2010 and based in Cambridge, Massachusetts, Moderna is known for its innovative approach to addressing unmet medical needs, particularly in vaccines for infectious diseases like COVID-19 and other respiratory viruses. With a strong pipeline of products targeting various health threats, the company is well-positioned in the rapidly evolving biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4,700
CEO
Mr. Stéphane Bancel M.B.A.
Country
United States
IPO Year
2018
Website
www.modernatx.comModerna, Inc. (MRNA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
Jul 17, 2026
By Zacks Equity Research
Analyst Blog
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.
Jul 13, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Moderna Inc. (NASDAQ:MRNA) will report Q2 results on July 31, with expected revenue of $50M-$100M, down from $389M. Investors are focused on seasonal COVID vaccine demand and melanoma trial updates.
Why It Matters
Moderna's upcoming earnings report may reveal a sharp revenue decline due to seasonal vaccine demand, impacting investor sentiment and stock performance amid pipeline developments.
Source: Proactive Investors
Market Sentiment:
Neutral
Quick Summary
Moderna (MRNA) closed at $66.98, marking a decrease of 1.89% from the previous trading day.
Why It Matters
Moderna's stock decline signals potential volatility and market sentiment changes, impacting investor confidence and future trading strategies.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Moderna has secured a contract with the European Commission to supply its respiratory syncytial virus vaccine to six European countries.
Why It Matters
Moderna's contract with the European Commission enhances revenue prospects, expands market reach, and boosts investor confidence in its vaccine pipeline and growth potential.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Moderna, Inc. (NASDAQ:MRNA) will host a conference call and webcast on July 31, 2026, at 8:00 a.m. ET to discuss its Q2 2026 financial results and provide a corporate update.
Why It Matters
Moderna's upcoming financial results and corporate update may impact its stock price and reveal insights into its performance and future prospects, influencing investor decisions.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Moderna, Inc. has appointed Michael McDonnell, former CFO of Biogen, to its Board of Directors and Audit Committee, effective July 8, 2026. He has over 35 years of financial leadership experience.
Why It Matters
Michael McDonnell's extensive financial leadership and experience may enhance Moderna's governance and strategic direction, potentially boosting investor confidence and company performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Biotech shares are declining midday Friday, impacting investors who pursued gains from the sector's strong performance in 2026.
Why It Matters
The biotech sector's downturn signals potential losses for investors who bought in during a peak, indicating volatility and risk in future investments.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Frequently Asked Questions About MRNA Stock
What is Moderna, Inc.'s (MRNA) stock forecast for 2027?
Based on our analysis of 18 Wall Street analysts, Moderna, Inc. (MRNA) has a median price target of $45.00. The highest price target is $79.00 and the lowest is $22.00.
Is MRNA stock a good investment in 2027?
According to current analyst ratings, MRNA has 3 Buy ratings, 17 Hold ratings, and 3 Sell ratings. The stock is currently trading at $61.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRNA stock?
Wall Street analysts predict MRNA stock could reach $45.00 in the next 12 months. This represents a -27.2% decrease from the current price of $61.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Moderna, Inc.'s business model?
Moderna generates revenue through the development and commercialization of mRNA-based therapeutics and vaccines. The company partners with governments and health organizations for vaccine distribution and also explores collaborations with pharmaceutical companies to expand its therapeutic applications, particularly in oncology and rare diseases.
What is the highest forecasted price for MRNA Moderna, Inc.?
The highest price target for MRNA is $79.00 from at , which represents a 27.8% increase from the current price of $61.82.
What is the lowest forecasted price for MRNA Moderna, Inc.?
The lowest price target for MRNA is $22.00 from at , which represents a -64.4% decrease from the current price of $61.82.
What is the overall MRNA consensus from analysts for Moderna, Inc.?
The overall analyst consensus for MRNA is neutral. Out of 18 Wall Street analysts, 3 rate it as Buy, 17 as Hold, and 3 as Sell, with a median price target of $45.00.
How accurate are MRNA stock price projections?
Stock price projections, including those for Moderna, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:42 AM UTC